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ABSTRACT
Stroke is a major neurological disorder characterized by an
increase in the Glu (glutamate) concentration resulting in
excitotoxicity and eventually cellular damage and death
in the brain. HIF-1 (hypoxia-inducible factor-1), a tran-
scription factor, plays an important protective role in
promoting cellular adaptation to hypoxic conditions. It is
known that HIF-1a, the regulatable subunit of HIF-1,
is expressed by astrocytes under severe ischaemia.
However, the effect of HIF-1 on astrocytes following Glu
toxicity during ischaemia has not been well studied. We
investigated the role of HIF-1 in protecting ischaemic
astrocytes against Glu toxicity. Immunostaining with GFAP
(glial fibrillary acidic protein) confirmed the morphological
modification of astrocytes in the presence of 1 mM Glu
under normoxia. Interestingly, when the astrocytes were
exposed to severe hypoxia (0.1% O2), the altered cell
morphology was ameliorated with up-regulation of HIF-1a.
To ascertain HIF-1’s protective role, effects of two
HIF-1a inhibitors, YC-1 [3-(50-hydroxymethyl-20-furyl)-1-
benzylindazole] and 2Me2 (2-methoxyoestradiol), were
tested. Both the inhibitors decreased the recovery in
astrocyte morphology and increased cell death. Given that
ischaemiaincreasesROS(reactiveoxygen species),weexamined
the role of GSH (reduced glutathione) in the mechanism for
this protection. GSH was increased under hypoxia, and this
correlated with an increase in HIF-1a stabilization in the
astrocytes. Furthermore, inhibition of GSH with BSO
(L-butathione sulfoximine) decreased HIF-1a expression,
suggesting its role in the stabilization of HIF-1a. Overall, our
resultsindicate that the expression of HIF-1aunder hypoxia has
a protective effect on astrocytes in maintaining cell morpho-
logy and viability in response to Glu toxicity.
Key words: brain ischaemia, cell viability, glutamate,
glutathione, hypoxia-inducible factor 1, stroke.
INTRODUCTION
B r a i ni s c h a e m i ai n d u c e sac a s c a d eo fe v e n t st h a ti n v o l v eal o s so f
glucose and oxygen, membrane depolarization, and Glu (glutam-
ate) release, leading to excitotoxicity. This release of the
neurotransmitter Glu and subsequent calcium influx
is considered to be the most significant event in the pathogenesis
of ischaemic brain damage. Astrocytes play an important role in
maintaining extracellular Glu that is released from neurons below
toxic levels. They do so by clearing up Glu from the synaptic
region through excitatory amino acid transporters and converting
the Glu into glutamine by glutamine synthetase. Glutamine is
then shuttled back to neurons and is re-used for Glu synthesis
(Lehmann et al., 2009). Astrocytes are also involved in the
metabolic support to neurons and provide them with nutrients
such as lactate to supplement energy requirements. In addition,
astrocytes appear to be the main source of EPO (erythropoietin)
and GSH (reduced glutathione) in the CNS (central nervous
system), having a GSH concentration twice as high that in
neurons (Bolanos et al., 1995). There is significant evidence of
astrocytes providing GSH and EPO to neighbouring neurons
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asnneuro.org / Volume 4 (4) / art:e00090 231against various stresses (Gabryel and Malecki, 2006). Previous
studies have shown that, in ischaemic infarcts, neurons do not
survive if neighbouring astrocytes are not viable (Takano et al.,
2009). Therefore it is important to examine how ischaemia
affects the function and viability of astrocytes.
Under ischaemic conditions, HIF-1 (hypoxia-inducible
factor-1) is expressed to promote cell survival. HIF-1 is a
heterodimeric protein formed by a continuously expressed
subunit HIF-1b and an oxygen-regulated subunit HIF-1a that is
stabilized under low oxygen levels. Activation of HIF-1 leads to
the transcription of various genes that contribute to the
cellular adaptation to these conditions. Some of the genes that
play an important role in the protective effect of HIF-1 are
those that are involved in angiogenesis such as VEGF (vascular
endothelial growth factor), erythropoiesis such as EPO and
genes involved in glucose metabolism such as glucose
transporters (Siddiq et al., 2007). It has been shown that HIF-
1 induces high levels of EPO expression in astrocytes (Masuda
et al., 1994), making them the main source of EPO in the CNS.
This demonstrates that HIF-1 plays an important role not only
in neurons but alsoin astrocytes. Inaddition, Glu release during
cerebral ischaemia causes the formation of ROS (reactive
oxygen species) by the disruption of the mitochondrial electron
transport chainand the activation ofNAPDH oxidases(Brennan
et al., 2009). Activation of HIF-1 has been shown to protect
astrocytes against oxidative damage (Chu et al., 2010).
Since astrocytes play an important role in maintaining
brain homoeostasis and providing neuroprotection, their
response to Glu toxicity and ischaemic insult requires further
understanding. The main objective of this study was to
investigate the effects of Glu on the viability and morphology
of astrocytes exposed to hypoxia and the role that HIF-1 plays
under these conditions. Our results demonstrate that HIF-1
has a protective effect on primary rat cortical astrocytes in
terms of increasing cell viability and maintaining cell
morphology in response to Glu toxicity and severe oxygen
deprivation. Furthermore, we show that GSH may contribute
to this protection by providing optimal conditions for HIF-1
stabilization.
MATERIALS AND METHODS
Primary culture of astrocytes
All experiments were conducted with the approval of the
University of Kansas Institutional Animal Care and Use
Committee. Cortical tissue were dissected from the
Sprague–Dawley rat (Charles River Laboratories) brains at
postnatal day 0 (P0) to P4. The tissues were washed with
HBSS (Hanks balanced salt solution) and trypsinized for
50 min at 37˚C. The tissues were then dissociated using a fire
polished glass pipette in a dissociation medium (HBSS, 0.1%
BSA and 8 mM MgCl2), and centrifuged at 4000 g for 4 min
at room temperature (22˚C). The cells were transferred into
and grown in 25 cm
2 flasks with DMEM (Dulbecco’s modified
Eagle’s medium) and 10% FBS (fetal bovine serum). After 3–4
weeks the flasks were shaken to purify the astrocytes by
dislodging other cell layers. Following purification, astrocytes
were plated on coverslips with DMEM and 10% FBS and used
for experiments after 10–12 days.
In vitro hypoxia model
Hypoxia was induced by incubating the astrocytes in 0.1%
O2/5% CO2 (balanced with N2) in a hypoxia chamber (COY
Laboratories) for 3 h. To mimic the high levels of Glu release
during ischaemia, astrocytes were treated with 0, 0.001, 0.01,
0.1and1 mMofGluinserum-freemedium(DMEM)at37˚Cfo r
3 h. Control experiments were conducted at 21% O2/5% CO2.
Drug treatments
YC-1 [3-(50-hydroxymethyl-20-furyl)-1-benzylindazole] and
2Me2 (2-methoxyoestradiol; Cayman Chemical Company)
were used for HIF-1a inhibition studies. Prior to hypoxia
exposure, the astrocytes were incubated with 0.1 mM of the
inhibitors for 1 h. Preliminary experiments showed that these
conditions were sufficient for HIF-1a inhibition during severe
hypoxia, as shown in Figure 3. For GSH depletion, astrocytes
were pre-incubated with 5 mM BSO (L-butathione sulfox-
imine; Sigma–Aldrich) for 12 h as described by Noda et al.
(2001). The BSO was present for an additional 3 h during the
hypoxia treatment to inhibit the re-synthesis of GSH.
Immunocytochemistry
Following treatments, astrocytes were washed with PBS and
fixed with 4% PFA (paraformaldehyde) for 20 min at room
temperature. The cells were then permeabilized using 0.3%
Triton X-100 for 15 min at room temperature and incubated in
a blocking solution (0.05% Triton X-100 and 0.25% BSA
dissolved in PBS) for 30 min at room temperature. Astrocytes
were incubatedwith primary antibodies ofGFAP (glial fibrillary
acidic protein) (1–500, MAB3402, Millipore) and HIF-1a (1–
100,sc-8711,SantaCruzBiotechnology)overnightat4˚C.Cells
were washed and incubated with the appropriate secondary
antibodies [GFAP: donkey anti-mouse TRITC (tetramethylrho-
damine b-isothiocyanate) (1–50; Jackson ImmunoResearch)
and HIF-1a: goat anti-rabbit conjugated to Alexa FluorH 488
(1–100; Molecular Probes)]. Coverslips were washed and
mounted by using Vectashield mounting medium with DAPI
(49,6-diamidino-2-phenylindole; Vector Laboratories). Images
were acquired on a Leica DMI4000 microscope with a 640
objective and a Leica DFC340 FX digital camera.
GSH measurement
The GSH level was measured by using the MCB (monochloro-
bimane) method (Chatterjee et al., 1999). Following the
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for 30 min at 37˚C. Fluorescence images were then taken
immediately, directly from the culture dish. For co-local-
ization studies, the astrocytes were fixed after the MCB
treatment and double-stained for GFAP and HIF-1a using the
immunocytochemistry procedure described above. The
intensity of the fluorescent GSH conjugate (GSH–MCB) of
single cells was measured from the images using ImageJ
software. Readings of whole-cell intensity were taken from
15 cells from three different culture preparations.
Cytotoxicity assessment
Cell death was assessed by measuring the activity of LDH
(lactate dehydrogenase) in the culture medium using an
LDH cytotoxicity assay kit (Cayman) as described by Bonfoco
et al. (1995). The MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl-2H-tetrazolium bromide] assay kit (Invitrogen) was
also used to assess cell survival and to quantify the Glu-
mediated cytotoxicity as described by Mosmann (1983).
Immunoblot analysis
Astrocytes were lysed in 200 ml of RIPA buffer (Thermo Sci-
entific) and the protease inhibitor cocktail kit (Thermo
Scientific) and scraped with the aid of a cell lifter (Biologix
Research Company). The lysates were centrifuged at 15300 g
for 10 min at 4˚C, and the protein concentration of the
supernatants was determined using a protein assay kit (Bio-
Rad). Proteins were separated by SDS/PAGE and the separated
proteins were transferred to a nitrocellulose membrane (Bio-
Rad). After being blocked with 5% (w/v) non-fat dried
skimmed milk powder in TBST (Tris-buffered saline with
Tween), the membrane was incubated with the primary
antibody (HIF-1a: 1–1000; BD Transduction Laboratories)
overnight at 4˚C and the secondary antibody (1–3000; goat
anti-mouse; Santa Cruz Biotechnology) for 1 h at room
temperature. Immunoblots were quantified using ImageJ
software and HIF-1a levels were normalized to b-actin.
Texture analysis
Changes in astrocyte texture were determined using
CellProfiler cell image analysis software as described previously
by Haralick et al. (1973) and Carpenter et al. (2006).
Quantification of texture was done from fluorescence images
from three different culture preparations. Five microscopic
fields were obtained from each culture dish and readings from
six to eight cells were taken for further analysis.
Statistical analysis
Data are presented as means¡S.D. from a minimum of three
independent experiments. One-way ANOVA and the Student’s
t test were used for overall significance. Differences of
P,0.05 were considered statistically significant. Image-Pro
Plus 5.1 (Media Cybernetics), ImageJ and Excel were used for
data analyses.
RESULTS
Severe hypoxia-protected astrocytes from Glu
toxicity
Excessive Glu accumulation is a major cause of neuronal
death in the brain during ischaemia. Astrocytes are very
important for the clearance of excessive Glu from the
extracellular space; however, high concentrations of Glu also
affect astrocytes and can lead to their death under normal
conditions. Here, we studied the morphological changes in
primary rat cortical astrocytes exposed to Glu at various
concentrations (0, 0.001, 0.01, 0.1 and 1 mM) for 3 h. The
morphology was assessed based on GFAP expression. Lower
concentrations (0.001 and 0.01 mM) of Glu had no effect
on the morphology. Increased concentrations (0.1 and
1 mM) caused changes in the structure of the astrocytes
(Figure 1A). Under control conditions, astrocytes appeared
fibrous. However, high Glu resulted in a disrupted or diffuse-
like structure. To quantify the GFAP-based structural/
morphological changes, we conducted texture analysis by
using CellProfiler which measures the amount of local
variation present (Carpenter et al., 2006). A higher value
with more contrast suggests a more complex structure. The
results demonstrate that Glu altered the astrocyte morpho-
logy under normoxia, compared with the control (no Glu).
Interestingly, when astrocytes were exposed to severe
hypoxia (0.1% O2) in the presence of 1 mM Glu, the
astrocyte morphology was improved when compared with
1 mM Glu under normoxia. These data are evidence that
hypoxia protects astrocytes against Glu toxicity. As the low
concentrations of Glu had no effects on astrocyte
morphology, the following studies were carried out with
0.1 and 1 mM Glu.
To further examine the protective effect of hypoxia on
astrocyte against Glu, we measured cell death with the LDH
assay as shown in Figure 1(C). Under normoxia, there was a
Glu-concentration-dependent decrease trend in astrocyte
viability. Under severe hypoxia there was a sign of recovery.
When cell viability was determined with the MTT assay, we
observed a significant decrease in cell viability when
astrocytes were exposed to 1 mM Glu under normoxia and
a significant recovery in astrocyte survival under hypoxia. The
difference in the cell viability may be due to the sensitivity of
the two cytotoxicity assays. The LDH assay requires a more
severe insult that causes damage to the cell membrane.
The MTT assay on the other hand works by measuring the
metabolic activity of the mitochondria. Nevertheless, results
from both assays indicate that hypoxia reduces astrocyte
damage caused by Glu.
HIF-1 protection in astrocytes
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233HIF-1a is highly expressed in astrocytes under
severe hypoxia
Next, we aimed to address the mechanism by which the
astrocytes recovered from the Glu toxicity during severe
hypoxia. It is known that HIF-1a is stabilized under low
oxygen levels and can contribute to cellular protection under
these conditions. HIF-1a expression was first analysed by
immunostaining. As expected, there was no HIF-1a expression
under normoxia, while treatments with severe hypoxia
Figure 1 Hypoxia ameliorated astrocyte damage induced by Glu
(A) Immunostaining characterization of cultured rat cortical astrocytes. Representative images depicting GFAP (red) in astrocytes
treated with 0, 0.001, 0.1, 0.1 and 1 mM Glu under normoxia (21% O2) and 1 mM exposed to severe hypoxia (0.1% O2) for 3 h. (B)
Morphological profiling of astrocytes stained for GFAP and DAPI (for nucleus staining). Individual cells were identified using
CellProfiler software and divided with clear boundaries (1). Representation (3) of quantification of morphology using one of the 13
features computed from each cell to measure and compare texture (2). *P,0.05 versus 0 mM Glu under normoxia. (C) Astrocyte
viability assessed using the LDH and MTT assay. *P,0.05 versus 0 mM Glu under normoxia,
#P,0.05 versus 1 mM Glu under
normoxia (n53).
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(Figure 2A). HIF-1a was also expressed in the nucleus of
the astrocytes following severe hypoxia treatment in the
presence of Glu. For further confirmation, Western-blot
analysis demonstrated a significant increase in HIF-1a protein
levels under severe hypoxia, both with and without Glu
treatments (Figure 2B). However, with 1 mM Glu under
severe hypoxia there was a slight decrease in the HIF-1a
protein levels. This could be due to increased proteasomal
degradation induced by an increase in ROS (see the
Discussion for further explanation).
HIF-1a inhibition attenuates the recovery of
astrocytes from Glu toxicity under severe
hypoxia
To confirm whether the recovery of the cell morphology and
cell viability under severe hypoxia was in fact due to the
expression of HIF-1a, the effect of two HIF-1a inhibitors,
YC-1 and 2Me2, were examined on astrocyte damage. Although
the mechanism of HIF-1ainhibition by YC-1 and 2Me2 is not fully
understood, it appears as though YC-1 acts at a post-translational
level and inhibits HIF-1a activation (Li et al., 2008), while 2Me2
inhibits HIF-1a at the level of translation (Mabjeesh et al., 2003).
Astrocytes were pre-treated with a 0.1 mM concentration of the
inhibitors for 1 h and then subjected to severe hypoxia with
the addition of 1 mM Glu for an additional 3 h. Astrocytes
t r e a t e dw i t hY C - 1o r2 M e 2s h o w e dm u c hl e s sH I F - 1 a expression
in the nuclei of astrocytes under severe hypoxia in the presence of
0 and 1 mM Glu (Figure 3A). The immunostaining also reveals
that the addition of either YC-1 or 2Me2 resulted in an
attenuation of the recovery of the cell morphology when
compared with the controls. Western blotting confirmed that the
inhibitors did decrease the HIF-1a protein level (Figure 3B).
Table 1 shows the effects of the two HIF-1 inhibitors on
cell morphology quantified by the texture analysis and cell
viability assays. Both YC-1 and 2Me2 treatments resulted in a
significant change in cell morphology and significant increase
Figure 2 HIF-1a expression was increased in astrocytes exposed to severe hypoxia and Glu
(A) Representative immunofluorescentimages showingGFAP(red)and HIF-1a (green)labelling inastrocytes treated with 0,0.1 and1 mM
GluunderN(normoxia)orSH(severehypoxia)for3 h.(B)ProteinstabilizationofHIF-1adeterminedbyWestern-blotanalysis.Equalization
of protein loading was determined using b-actin as the housekeeping protein. *P,0.05 versus 0 mM Glu under normoxia (n53).
HIF-1 protection in astrocytes
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235in cell death. Astrocytes treated with the HIF-1a inhibitors
under normoxia showed no significant effect (Table 1). The
increase in cell death was consistent with no recovery in
texture with either YC-1 or 2Me2 treatment under severe
hypoxia. This suggests that the recovery in astrocyte
morphology is caused by the stabilization of HIF-1a under
low oxygen levels.
GSH stabilizes HIF-1a expression
GSH is the most abundant small molecule anti-oxidant that
suppresses free radical levels and protects cells against
various stress conditions. Previous data from our laboratory
has shown that GSH increases HIF-1a expression during
oxygen deprivation (Guo et al., 2008). To determine whether
GSH plays a role in the HIF-1a stability and protective effect
in astrocytes, we compared GSH levels between the different
treatments. The cellular GSH level was measured using the
MCB method. Fluorescence intensities of GSH-MCB were
quantified to differentiate between the levels of GSH present
in astrocytes treated with 0.1 and 1 mM Glu under normoxia
versus severe hypoxia. The results showed no change in GSH
levels in the presence of Glu lower than 0.1 mM under
normoxia; however, 1 mM Glu caused a significant in-
crease in GSH (Figures 4A and 4B). Hypoxia increased the GSH
levels in astrocytes. The presence of Glu further increased the
GSH level in astrocytes exposed to hypoxia.
To determine whether an increase in GSH levels con-
tributed to the up-regulated HIF-1a expression, we fixed the
cells after MCB treatment with or without severe hypoxia
in the presence of Glu and then co-stained for GFAP and HIF-
1a. The results showed a co-localization of increased GSH
with HIF-1a expression in astrocytes treated with both 0.1
and 1 mM Glu (Figure 4C). This suggests that GSH might help
stabilize HIF-1a expression in the astrocytes. To confirm the
role of GSH in the HIF-1a up-regulation, astrocytes were pre-
treated with 5 mM BSO, which decreases cellular GSH levels,
for 12 h and then exposed to Glu and hypoxia. This resulted
in a significant attenuation of HIF-1a stabilization (Figure 5).
Furthermore, inhibition of GSH and consequently HIF-1a,
decreased astrocyte survival and abolished the morphological
recovery under hypoxia (Table 2). These results are consistent
with the results of HIF-1a inhibition using YC-1 and 2Me2;
indicating that HIF-1 provides protection against Glu in
hypoxic astrocytes.
DISCUSSION
To date, there are no effective neuroprotectants for human
stroke, and the development of neuroprotective strategies is
considered extremely challenging. Although many agents
have been tested for the treatment of ischaemic stroke, such
as anti-oxidative, anti-apoptotic, anti-excitotoxic and anti-
inflammatory drugs, they have all proved unsuccessful. One of
the reasons for this may be our incomplete understanding
of the mechanisms that are responsible for cellular death.
Furthermore, the study of cell death following cerebral
ischaemia has been primarily focused on neurons. In addition
to neurons, ischaemia also causes damage to astrocytes
(Martin et al., 1997; Yu et al., 2001; Lukaszevicz et al., 2002;
Giffard and Swanson, 2005), which are critical in maintaining
neuronal viability and functions under ischaemic conditions.
Therefore targeting astrocytes can be an important strategy
to enhance neuronal survival.
Figure 3 YC-1 and 2Me2 attenuated the protection provided by hypoxia
in astrocytes
(A) Representative immunofluorescent images demonstrating the effect of YC-1
and 2Me2 on HIF-1a (green) expression and astrocyte morphology (GFAP, red).
Astrocytes were pre-treated with 0.1 mM YC-1 and 2Me2 followed by 1 mM Glu
with exposure to N (normoxia) or SH (severe hypoxia) 3 h. (B) Protein stabilization
of HIF-1a determined by Western-blot analysis. Equalization of protein loading
was determined using b-actin as the housekeeping protein. *P,0.05 versus 0 mM
Glu under normoxia,
#P,0.05 versus 0 mM Glu under severe hypoxia (n53).
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Results are presented as means¡S.D. (n53). N, normoxia; SH, severe hypoxia. *P,0.05 versus normoxia. **P,0.05 versus normoxia
1 mM.
#P,0.05 versus severe hypoxia 0 mM.
Cell viability (%)
Glu concentration Treatment Texture analysis LDH assay MTT assay
0 mM N 1.49¡0.12 100 100
N+YC-1 1.19¡0.04 99.12¡3.09 98.22¡1.74
N+2Me2 1.13¡0.03 99.47¡2.52 97.95¡2.57
SH 1.07¡0.24 97.35¡1.79 90.82¡2.93
SH+YC-1 0.97¡0.31 66.15¡6.42
# 62.74¡2.20
#
SH+2Me2 0.89¡0.28 66.34¡1.96
# 64.41¡3.09
#
1 mM N 0.52¡0.06* 94.09¡1.49 82.84¡1.77*
N+YC-1 0.44¡1.08* 98.29¡1.51 80.42¡5.03*
N+2Me2 0.48¡1.11* 97.30¡3.24 81.03¡4.12*
SH 0.89¡0.05** 95.17¡3.42 89.86¡4.02
SH+YC-1 0.55¡0.11* 59.44¡3.59
# 55.91¡5.24
#
SH+2Me2 0.51¡0.05* 65.56¡5.14
# 58.62¡3.37
#
Figure 4 Astrocyte GSH levels were increased with Glu and severe hypoxia treatments
Astrocytes were treated with 0.1 mM or 1 mM Glu with exposure to N (normoxia) or SH (severe hypoxia) for 3 h. Astrocytes were
loaded with 0.1 mM MCB following treatments. (A) Representatives of GSH-MCB labelling in astrocytes exposed to various
conditions. (B) Quantification of the cytosolic GSH intensity in astrocytes exposed to various conditions. *P,0.05 versus 0 mM Glu
under normoxia,
#P,0.05, normoxia versus severe hypoxia for each Glu concentration. (C) Co-localization of GFAP (red), HIF-1a
(green) and GSH (blue) in astrocytes treated with 0, 0.1 and 1 mM Glu under normoxia or severe hypoxia (n53).
HIF-1 protection in astrocytes
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237Recently, HIF-1 is being focused on as a potential target
for stroke therapy as it appears to have many beneficial roles
in the ischaemic brain (Baranova et al., 2007). Although HIF-1
has been shown to have a protective effect specifically in
astrocytes in neurological diseases such as Alzheimer’s disease
(Schubert et al., 2009), few studies have been done to
investigate the effect of HIF-1a expression on astrocytes
during stroke.
Given the increase in Glu in the ischaemic brain and the
scavenging function of astrocytes on Glu, we examined
the effects of Glu on the viability and morphology of
astrocytes exposed to hypoxia. Compared with neurons,
astrocytes are very resistant to hypoxia due to several factors.
First, astrocytes have large glycogen stores (Phelps, 1972)
that can be metabolized to glucose and lactate and supply
energy during ischaemia and glucose deprivation (Swanson
Figure 5 GSH inhibition reduces HIF-1a expression
(A) Representative immunofluorescence images demonstrating the effect of BSO on HIF-1a (green) expression and astrocyte
morphology. Astrocytes were pre-treated with 5 mM BSO followed by 1 mM Glu with exposure to SH (severe hypoxia) and compared
with astrocytes treated with 0 and 1 mM Glu under severe hypoxia only. HIF-1a intensity was measured and normalized to the
control. *P,0.05 versus 0 mM Glu under normoxia,
#P,0.05 versus 1 mM Glu under severe hypoxia. (B) Immunoblotting showing
HIF-1a protein levels. Equalization of protein loading was determined using b-actin as the housekeeping protein. Quantitative results
for Western blot data. *P,0.05 versus 0 mM Glu under normoxia. (n53).
Table 2 Effect of BSO on HIF-1a-induced protection of astrocytes
Results were presented as means¡S.D. (n53). N, normoxia; SH, severe hypoxia. *P,0.05 versus severe hypoxia.
#P,0.05 versus
severe hypoxia 1 mM.
Cell viability (%)
Glu concentration Treatment Texture analysis LDH assay MTT assay
0 mM SH 1.10¡0.13 100 100
SH+BSO 0.59¡0.18* 63.70¡3.29* 57.36¡4.69*
1 mM SH 0.96¡0.13* 96.14¡1.17 97.06¡2.37
SH+BSO 0.54¡0.17*
# 60.68¡2.79*
# 54.35¡5.26*
#
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demand, unlike neurons, which have a high density of ion
channels and require more ATP to maintain ionic gradients.
Thus ionic deregulation occurs slowly in astrocytes (Silver
et al., 1997). Thirdly, astrocytes have a higher level of GSH, an
important antioxidant, than neurons and provide GSH or
substrates for GSH synthesis to neurons (Makar et al., 1994,
Chen and Swanson 2003). In our experiments, astrocytes were
exposed to severe hypoxia (0.1% O2) because a milder hypoxic
exposure (1% O2) was not sufficient to cause any significant
changes in HIF-1a expression (data not shown). As the results
demonstrated, Glu caused a concentration-dependent change
in astrocyte morphology, which resembled a more diffuse-like
structure from a fibrous one, under normoxia. This was
correlated with a decrease in cell viability determined by LDH
and MTT assays. Interestingly, when the astrocytes were
treated with the same Glu concentrations under severe
hypoxia there was a recovery in cell morphology and cell
viability. Our observation is consistent with a previous study
that demonstrated that pre-treatment with hypoxia reduced
astrocyte damage by 45–55% (Chen et al., 2000).
One of the remarkable observations in our study is that
increased GSH is not sufficient to protect astrocytes from
damage induced by Glu under normoxia. As shown in
Figures 4(A) and 4(B), Glu at 1 mM significantly elevated
the GSH level in astrocyte under normoxia and induced
significant cell damage detected by cellular texture and
viability (Figure 1). In contrast, under hypoxic conditions
the increase of GSH was accompanied by improved cellular
texture and astrocyte viability (Figures 1 and 4). This
protective effect provided in the hypoxic conditions is largely
ascribed to the expression of HIF-1, since inhibiting HIF-1
abolished the protection (Figure 3 and Table 1). Furthermore,
stabilizing HIF-1a expression under normoxia with cobalt
chloride appeared to have an even more significant effect in
the recovery of cell morphology (Supplementary Figure S1B
available at http://www.asnneuro.org/an/004/an004e090add.
htm). Taken together, these findings strongly support that the
activation of HIF-1 is responsible for promoting the astrocytic
survival and protection against Glu toxicity under hypoxia.
Many factors may contribute to HIF-1-mediated protection
in hypoxic astrocytes. First, HIF-1 up-regulates EPO (Semenza
et al., 1997), which provides cellular protection under
different stresses. Many studies have examined the effect
of EPO on astrocytes, since they are the main source of EPO in
the brain. For example, EPO has been shown to protect
astrocytes from damage in response to oxidative stress (Liu
et al., 2006) and other agents that induce apoptosis
(Diaz et al., 2005). Secondly, HIF-1 leads to the induction of
VEGF in astrocytes (Sinor et al., 1998). VEGF has been shown
to play an important role in cellular protection in hypoxic
preconditioning (Wick et al., 2002) by promoting angiogen-
esis (Jin et al., 2000). A study by Mani et al. (2005) has
revealed that exogenous VEGF induces astrocyte proliferation.
In addition, HIF-1 may promote the production of adenosine
that offers neuroprotective properties (Heurteaux et al.,
1995; Wardas 2002; Lin et al., 2008). Adenosine binds to the
presynaptic A1 receptor and may lead to a decrease in Ca
2+
influx. This further decreases the release of Glu and excitation
of the NMDA (N-methyl-D-aspartate) receptors, thus pre-
venting cellular damage caused by the subsequent increases
in Ca
2+ influx (Monopoli et al., 1998; Wardas 2002). A study
by Batti et al. (2010) has shown that the stabilization of HIF-
1a through prolyl hydroxylase inhibition protected against
Glu-induced damage in the hippocampus of the rat ischaemic
brain mainly through adenosine accumulation in response to
hypoxia. A review article by Vangeison and Rempe (2009)
clearly describes how hypoxia and HIF-1 can regulate various
proteins, including connexin 43, CD73 and the ENT-1
(equilibrative nucleoside transporter 1), which ultimately
leads to enhanced adenosine levels. Of these, both CD73 and
ENT-1 have been shown to be regulated by HIF-1 in intestinal
epithelia (Synnestvedt el al. 2002) and endothelial cells
(Eltzschig et al., 2005) respectively. CD73 and ENT-1 are
expressed in astrocytes (Vangeison and Rempe 2009);
therefore it is possible that HIF-1 can regulate their activity
and increase adenosine in astrocytes. In fact, it has been
shown that adenosine has a direct protective effect on rat
primary astrocytes by reducing death induced by glucose
deprivation (Shin et al., 2002) and in reducing damage in
human astroglioma D384 cells following oxygen deprivation
through the preservation of ATP levels (Bjorklund et al.,
2008).
Figure 6 Schematic diagram of GSH–HIF-1 cross-talk in promoting cell
survival during hypoxia
Hypoxia leads to HIF-1 stabilization which subsequently activates the
expression of various pro-survival genes. These include EPO, VEGF, HSPs, HO-
1 and proteins that increase glucose metabolism such as glucose transporters
and glycolytic enzymes. Genes such as those of glucose metabolism,
HSPs and HO-1 may increase the level of GSH causing it to exert its anti-
oxidant effect and promote survival. In addition, the reducing environment
created by GSH can in turn contribute to HIF-1 stabilization.
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239The results presented in this paper clearly demonstrate that
GSH increases the HIF-1a level in astrocytes exposed to
hypoxia. As shown in Figure 4, there was an increase in GSH
following the 3 h Glu and severe hypoxia treatment. In
addition, BSO, which inhibits GSH synthesis, decreased HIF-1a
expression. Our results are consistent with previous studies
that have shown that altering redox status can effect HIF-1a
expression in other types of cells. Inhibition of GSH synthesis
by BSO reduced HIF-1a expression in lung epithelial cells
(Haddad and Land, 2000) and in hepatic cells (Jin et al., 2011).
Treatment with N-acetylcysteine, the GSH precursor,
increased HIF-1a expression in lung epithelial cells (Haddad
et al., 2000) and in hepatic cells (Sommani et al 2007;
Jin et al., 2011). Our previous results have also demonstrated
that HIF-1a stability favours a reducing environment in
neurons (Guo et al., 2008). Recently, Tajima et al. (2009)
showed that the induction of HIF under hypoxia is regulated
by the redox state of GSH in HSC-2 (human oral squamous
cells). They suggest that GSH can regulate the activation of
HIF by directly binding to the thiol groups of regulatory
cellular proteins. Since HIF-1a is sensitive to redox status and
can be degraded by increased ROS (Liu et al., 2004; Wellman
et al., 2004), it is reasonable to consider that the mechanism
by which GSH increases HIF-1a is through the clearance of
excessive ROS and by promoting a suitable reducing
environment that prolongs its stabilization. Our immunoblot
results showed that, under normoxia, there was an increase in
HIF-1a levels when astrocytes were treated with 1 mM Glu.
Even though this increase was not significant, it did correlate
with increased GSH levels. It seems as though GSH is able
to stabilize HIF-1a and reduce its degradation when it is
normally expressed during hypoxia. However, during nor-
moxia, the oxygen levels are sufficient to maintain prolyl
hydroxylase activity and target HIF-1a for ubiquitination.
Meanwhile, HIF-1 may increase the level of GSH in hypoxic
astrocytes, as shown in our results. Others have also reported
that HIF-1 is able to maintain GSH levels in brains of rats
exposed to hypoxia (Shrivastava et al, 2008). In addition,
previous studies have shown that HIF-1 can protect
astrocytes from ROS-induced injury (Chu et al., 2010) and
that GSH depletion induces astrocytic death in response to
ROS (Im et al., 2006). All these results indicate that
maintaining GSH levels and reducing ROS toxicity is part of
HIF-1-mediated neuroprotection. Based on our results and
others, we postulate the GSH–HIF-1 crosstalk in hypoxic
astrocytes (Figure 6). Hypoxia induces accumulation of HIF-1,
which subsequently switches on the expression of genes that
promote cell survival such as glucose transporters and
glycolytic enzymes, EPO, VEGF, HSPs (heat-shock proteins)
(Baird et al., 2006), HO-1 (haem oxygenase 1) (Shrivastava
et al., 2008), etc. Some of the genes such as EPO and VEGF
provide direct cell protection against hypoxic stress. Others,
such as those of glucose metabolism, HSPs and HO-1, may
increase the level of GSH, contributing to HIF-1 stabilization.
In conclusion, there are still large gaps that exist in our
understanding of how astrocytes are affected during stroke.
Given that the release of the Glu is considered to be the
leading cause of brain damage following stroke, we
determined the effect of HIF-1a expression and stabilization
on how astrocytes respond to Glu toxicity during stroke. Our
study has shown that HIF-1a expression protects astrocytes
from Glu-induced damage. We also provide evidence that
GSH plays a role in HIF-1a stabilization and promotes its
protective effect. Taking this fact into consideration will lead
to a better understanding of the protective mechanisms of
astrocytes and provide a more effective approach not only to
stroke therapy but also other pathological conditions that
cause, or are exacerbated by, excitotoxicity.
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